75693-17-3

Usage

Uses

Used in Organic Synthesis:
6-Bromo-1,2-dihydro-naphthalene is used as a building block in the synthesis of various organic compounds and pharmaceuticals. Its unique structure allows for versatile chemical reactions, making it a valuable intermediate in the creation of a wide range of molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-bromo-1,2-dihydro-naphthalene is used as a key component in the development of new therapeutic agents. Its reactivity and structural properties enable the design and synthesis of novel drug candidates with potential applications in treating various diseases and medical conditions.
Used in Organic Chemistry Research:
6-Bromo-1,2-dihydro-naphthalene also serves as a reagent in organic chemistry research. It is involved in the synthesis of other chemical compounds through various reactions, contributing to the advancement of chemical knowledge and the discovery of new chemical processes.
Used in Drug Discovery:
6-BROMO-1,2-DIHYDRO-NAPHTHALENE has potential applications in drug discovery, where its unique properties can be leveraged to develop new and effective medications. Its role in this field is significant, as it can lead to the creation of innovative treatments and therapies for a variety of health issues.

InChI:InChI=1/C10H9Br/c11-10-6-5-8-3-1-2-4-9(8)7-10/h2,4-7H,1,3H2

Upstream product

• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 75693-15-1 7-bromo-1,2,3,4-tetrahydronaphthalen-1-ol 
• 35656-89-4 4-(4-bromophenyl)butanoic acid 

Downstream Products

• 2717-47-7 1,2-dihydro-6-methylnaphthalene 
• 75693-20-8 7-bromo-1,2-epoxy-1,2,3,4-tetrahydronaphthalene 
• 1373215-27-0 (1S,2S)-1-amino-7-bromo-1,2,3,4-tetrahydronaphthalen-2-ol (2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate 
• 1617524-93-2 C₁₆H₁₄ 
• 1373215-33-8 N-((1S,2S)-7-bromo-2-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-4-fluorobenzamide 
• 1373215-38-3 tert-butyl 4-((7S,8S)-8-(4-fluorobenzamido)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxopiperazine-1-carboxylate 
• 1373215-40-7 tert-butyl 4-((7S,8S)-8-(4-fluorobenzamido)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)piperazine-1-carboxylate 
• 1373215-41-8 4-fluoro-N-((1S,2S)-2-hydroxy-7-(piperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)benzamide hydrochloride 
• 1373215-17-8 (1S,2S)-1-(4-fluorobenzamido)-7-(4-(oxetan-3-yl)piperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methylcarbamate 
• 794507-89-4 (+/-)-1-amino-7-bromo-1,2,3,4-tetrahydronaphthalene 
• 22531-20-0 6-ethyltetralin 
• 42775-77-9 6-Propyl-tetralin 
• 1680-51-9 6-methyl-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Catalytic asymmetric intermolecular bromoesterification of unfunctionalized olefins

An asymmetric intermolecular bromoesterification of unfunctionalized olefins catalyzed by (DHQD)2PHAL is described. Optically active bromoesters can be obtained with up to 92% ee.

Direct oxidative allylic and vinylic amination of alkenes through selenium catalysis

Bringing "N" into the game: The direct chemoselective nitrogenation of unactivated alkenes can be achieved through oxidative selenium catalysis (see scheme). This method provides a broad variety of allylic imides in yields of up to 89 % using N-fluorobenzenesulfonimide (NFSI) as the terminal oxidant and nitrogen source. Furthermore, an unprecedented selenium-catalyzed vinylic C(sp2)-H nitrogenation was discovered. Copyright

Cathepsin S Inhibitor Compounds

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

Piperazine compounds

A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.

AROMATIC SUBSTITUENT EFFECT ON THE STEREOSELECTIVITY OF THE ACID-INDUCED RING OPENING OF 1,2-EPOXIDES DERIVED FROM 3,4-DIHYDRONAPHTHALENE. IMPORTANCE OF THE REACTIVE CONFORMATIONS FOR THE STEREOSELECTIVITY.

The stereochemistry of the acid-induced ring opening reactions (hydrolysis, methanolysis and trichloroacetolysis) of 1,2-epoxides derived from ring substituted 3,4-dihydronaphthalene has been examined.In every case, a satisfactory Hammett-type linear correlation was found between the diastereoselectivity of the reaction and the ?+ constant of the aromatic substituent.The stereoselectivity of the opening reaction turned out to be largely driven by the reactive conformation of the epoxide and/or of the opening process intermediates.

Synthesis of Biological Markers in Fossil Fuels. 2. Synthesis and 13C NMR Studies of Substituted Indans and Tetralins

Unambiguous syntheses of all possible methyl, ethyl, n-propyl, and n-butyl derivatives of indan and tetralin were developed using the Kumada coupling procedure involving the reaction of aryl or vinyl halides with Grignard reagents in the presence of nickel(II) chloride.An analysis of the 13C NMR spectra of these compounds was also completed.

Hydrocarbures arylaliphatiques. Partie VII. Orientation dans la reaction de bromation de benzocyclenes bi- et tricycliques superieurs

The bromination of 1,2,3-trimethylbenzene, and bi- and tricyclic fused ring systems (i.e. indan, tetralin, benzosuberan, 2a,3,4,5-tetrahydroacenaphthen and higher homologues) is described in this paper.This work is part of a research project studying the ring size influence of peri-fused semi-aromatic ring system on benzene reactivity.This study was started in a first step on acetylation and was continued on bromination.Forthcoming studies (now underway) concern the kinetic measurement of protodesilylation of univocal silyl derivatives.The synthesis of the starting bromo derivatives used for this latter study is described here.These bromides were used for the attribution via NMR spectroscopy of the electrophile reaction site in the direct bromination of the fused ring unsymmetrical systems (the reactive sites are obvious in symmetrical molecules). Thus, meta substitution is predominant in the case of tetraline and benzosuberan, but ortho substitution is relatively more important in tetralin.In 1,2,3-trimethylbenzene and the fused tricyclic compounds, substitution takes place in an ortho position respective to the substituent or the ring system, the meta position being totally deactivated.In the special case of a five-membered ring, the ortho position this ring is always non reactive.The reactivity differences between these compounds are explained by hyper conjugation and the stabilities of the transition states.

Synthesis and Immunological Activity of 5,6,6a,8,9,11a-Hexahydronaphthimidazothiazoles and 5,6,6a,9,10,11a-Hexahydronaphthimidazothiazoles

A series of 5,6,6a,8,9,11a-hexahydronaphthimidazothiazoles (17 and 20) and 5,6,6a,9,10,11a-hexahydronaphthimidazothiazoles (18) has been synthesized with cis- and/or trans-1,2-diamino-1,2,3,4-tetrahydronaphthalenes (12) as the key intermediates and subsequently evaluated for immunological activity (effects on antibody formation and delayed-type hypersensitivity reaction).Among the compounds tested, trans-5,6,6a,8,9,11a-hexahydronaphthimidazo(2,1-b>thiazole (trans-17a) and (+/-)-5,6,6aβ-8,9,11aα-hexahydro-8β-hydroxy-9β-methyl-8α-phenylnaphthimidazothiazole (20a) showed the largest immunological activity in mice with a magnitude comparable to that of levamisole and were found to be considerably less toxic than levamisole in an acute toxicological study.The structures of 18a and 20a were determined by X-ray crystallography.